Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Franz Humer Insider Profile
4 Followers
Franz Humer, Director at Citigroup, holds 316.73K shares in Allogene Therapeutics (Ticker: ALLO), holds 23.97K shares in Citigroup (Ticker: C), holds 0.00 shares in Kite Pharma Inc (Ticker: KITE).
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+11.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Franz Humer
Franz Humer's Trading History
Citigroup
Apr 02, 2019
Director
Uninformative Buy
10.40K
$1.70M
Allogene Therapeutics
Jun 07, 2024
Director
Uninformative Buy
―
$722.14K
Kite Pharma Inc
Oct 05, 2017
―
Uninformative Sell
832.32K
$0.00
List of latest transactions for each holding click on a transaction to see Franz Humer's performance on stock
You May Also Like
Franz Humer insider profile FAQ
What is the percentage of profitable transactions made by Franz Humer?
The percentage of profitable transactions made by Franz Humer is 100%.
What is the average return per transaction made by Franz Humer?
The average return per transaction made by Franz Humer is 11.50%.
What stocks does Franz Humer hold?
Franz Humer holds: C, ALLO, KITE stocks.
What was Franz Humer’s latest transaction?
Franz Humer latest transaction was an Uninformative Buy of ―.
What was Franz Humer's most profitable transaction?
Franz Humer’s most profitable transaction was an Informative Sell of ALLO stock on June 3, 2024. The return on the trade was 11.90%.
What is Franz Humer's role in Citigroup?
Franz Humer's role in Citigroup is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.